2021/02/25 17:38:08 | |
---|---|
Price | |
1,216.00 GBp | |
Difference | 0.25% (3.00) |
ISIN | GB0009252882 |
Symbol | GSK |
Exchange | London Stock Exchange |
Currency | GBp |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 70,732 EUR |
Benchmark | FTSE 100 |
Bid (Bid size) | 1,215.00 GBp (1,335) |
Ask (Ask size) | 1,215.60 GBp (485) |
Open | 1,215.00 GBp |
High | 1,220.40 GBp |
Low | 1,204.80 GBp |
Close (prev. day) | 1,213.00 GBp |
VWAP | 1,213.690218 GBp |
Volume (pcs) | 6,012,069 |
Trading volume | 7,296,789,338.00 |
Number of trades | 12,641 |
Last size | - |
Related Futures | 43 |
Related Options | - |
Date | Headline | Download | |
2021/02/15 |
![]() |
Global Equity Ratings |
![]() |
2021/02/15 |
![]() |
Aktienempfehlungen Global |
![]() |
2021/02/04 |
![]() |
Global Equity Ratings |
![]() |
2021/02/04 |
![]() |
Aktienempfehlungen Global |
![]() |
2021/01/08 |
![]() |
Global Equity Ratings |
![]() |
2021/02/25 17:38:08 | |
---|---|
Price | |
1,216.00 GBp | |
Difference | 0.25% (3.00) |
ISIN | GB0009252882 |
Symbol | GSK |
Exchange | London Stock Exchange |
Currency | GBp |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 70,732 EUR |
Benchmark | FTSE 100 |
Bid (Bid size) | 1,215.00 GBp (1,335) |
Ask (Ask size) | 1,215.60 GBp (485) |
Open | 1,215.00 GBp |
High | 1,220.40 GBp |
Low | 1,204.80 GBp |
Close (prev. day) | 1,213.00 GBp |
VWAP | 1,213.690218 GBp |
Volume (pcs) | 6,012,069 |
Trading volume | 7,296,789,338.00 |
Number of trades | 12,641 |
Last size | - |
6M | 1Y | 3Y | |
Perf (%) | -16.52% | -26.64% | -4.23% |
Perf (abs.) | -2.84 | -5.21 | -0.63 |
Beta | 0.87 | 0.66 | 0.70 |
Volatility | 21.51 | 32.27 | 23.55 |
Ø price 5 days | Ø volume 5 days (pcs.) | 1,217.48 GBp (10,854,860) |
Ø price 30 days | Ø volume 30 days (pcs.) | 1,317.97 GBp (8,754,479) |
Ø price 100 days | Ø volume 100 days (pcs.) | 1,365.71 GBp (8,094,891) |
Ø price 250 days | Ø volume 250 days (pcs.) | 1,492.26 GBp (8,032,071) |
YTD High | date | 1,446.60 GBp (2021/01/07) |
YTD Low | date | 1,196.00 GBp (2021/02/23) |
52 Weeks High | date | 1,772.51 GBp (2020/04/02) |
52 Weeks Low | date | 1,196.00 GBp (2021/02/23) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2021/02/25 | 17:35 | 14.27 EUR | 2.33 | 209 |
Tradegate | 2021/02/25 | 17:42 | 14.184 EUR | 0.80 | 187 |
Stuttgart | 2021/02/25 | 16:46 | 14.238 EUR | 0.04 | 16 |
SIX Swiss Exchange | 2020/04/21 | 17:36 | 21.50 CHF | 0.00 | 1 |
Munich | 2021/02/25 | 15:58 | 14.19 EUR | 0.02 | 3 |
London Stock Exchange | 2021/02/25 | 17:38 | 1,215.60 GBp | 7,296.79 | 12,641 |
Hanover | 2021/02/25 | 08:02 | 14.328 EUR | 0.00 | 1 |
Hamburg | 2021/02/25 | 16:29 | 14.248 EUR | 0.03 | 2 |
Frankfurt | 2021/02/25 | 17:37 | 14.20 EUR | 0.09 | 17 |
FINRA other OTC Issues | 2021/02/25 | 16:54 | 16.95 USD | 0.12 | 8 |
Duesseldorf | 2021/02/25 | 08:20 | 14.322 EUR | 0.00 | 1 |
Berlin | 2021/02/25 | 08:08 | 14.322 EUR | 0.00 | 1 |
GLAXOSMITHKLINE PLC |
- - |
Great West Road 980 TW8 9GS UK-Brentford, Middlesex |
Telefon: +44-20-8047-5000 |
Fax: - |
E-mail: GSK.Investor-Relations@gsk.com |
GSK is a british pharmaceutical and healthcare company. GSK manufactures drugs and vaccines for major disease areas such as asthma, cancer, infections, diabetes, digestive and mental health conditions. Many medicines were historically discovered or developed at GSK and its predecessor companies and are now sold as generics. |
Emma Walmsley | Chairman of Managing Board |
Sally Jackson | Member of Executive Committee |
Roger Connor | Member of Executive Committee |
Regis Simard | Member of Executive Committee |
Phil Thomson | Member of Executive Committee |
Nick Hirons | Member of Executive Committee |
Luke Miels | Member of Executive Committee |
Karenann Terrell | Member of Executive Committee |
James Ford | Member of Executive Committee |
Iain Mackay | Member of Executive Committee |
Diana Conrad | Member of Executive Committee |
Deborah Waterhouse | Member of Executive Committee |
David Redfern | Member of Executive Committee |
Brian McNamara | Member of Executive Committee |
Hal Barron | Member of Executive Committee |
Jonathan Symonds | Chairman of Supervisory Board |
Urs Rohner | Member of Supervisory Board |
Manvinder Singh Banga | Member of Supervisory Board |
Lynn Elsenhans | Member of Supervisory Board |
Judy Lewent | Member of Supervisory Board |
Iain Mackay | Member of Supervisory Board |
Emma Walmsley | Member of Supervisory Board |
Charles Bancroft | Member of Supervisory Board |
Vivienne Cox | Member of Supervisory Board |
Laurie Glimcher | Member of Supervisory Board |
Jesse Goodman | Member of Supervisory Board |
Hal Barron | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).
The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.
Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.
The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.
By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.
(iV) It is no consumer.